Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease
NCT04619680Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2020
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of nintedanib in interstitial lung disease (ILD), sponsored by Icahn School of Medicine at Mount Sinai. Started Nov 2020; status: completed.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04619680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619680.